Rodrigues Claire R, Harrington Amanda R, Murdock Nicole, Holmes John T, Borzadek Eliza Z, Calabro Kristin, Martin Jennifer, Slack Marion K
1 JPS Health Network, Fort Worth, TX, USA.
2 University of Arizona, Tucson, AZ, USA.
Ann Pharmacother. 2017 Oct;51(10):866-889. doi: 10.1177/1060028017712725. Epub 2017 Jun 9.
To describe pharmacy-supported transition-of-care (TOC) interventions and determine their effect on 30-day all-cause readmissions.
MEDLINE/PubMed, EMBASE, International Pharmaceutical Abstracts, ABI Inform Complete, PsychINFO, Web of Science, Academic Search Complete, CINHAL, Cochrane library, OIASTER, ProQuest Dissertations & Theses, ClinicalTrials.gov , and relevant websites were searched from January 1, 1995, to December 31, 2015.
PICOS+E criteria were utilized. Eligible studies reported pharmacy-supported TOC interventions compared with usual care in adult patients discharged to home within the United States. Studies were required to evaluate postdischarge outcomes (eg, rate of readmissions, hospital utilization). Randomized controlled trials, cohort studies, or controlled before-and-after studies were included. Two reviewers independently extracted data and evaluated study quality.
A total of 56 articles were included in the systematic review (n = 61 858), of which 32 reported 30-day all-cause readmissions and were included in the meta-analysis. A taxonomy was developed to categorize targeted patients, intervention types, and pharmacy personnel as sole intervener. The meta-analysis demonstrated about a 32% reduction in the odds of readmission (odds ratio [OR] = 0.68; 95% CI = 0.61 to 0.75) observed for pharmacy-supported TOC interventions compared with usual care. Heterogeneity was identified ( I = 55%; P < 0.001). A stratified meta-analysis showed that interventions with patient-centered follow-up reduced 30-day readmissions relative to studies without follow-up (OR = 0.70; CI = 0.63 to 0.78).
Pharmacy-supported TOC programs were associated with a significant reduction in the odds of 30-day readmissions.
描述药学支持的照护过渡(TOC)干预措施,并确定其对30天全因再入院率的影响。
检索了1995年1月1日至2015年12月31日期间的MEDLINE/PubMed、EMBASE、国际药学文摘、ABI Inform Complete、PsychINFO、科学引文索引、学术搜索完整版、护理学与健康领域数据库、考科蓝图书馆、OIASTER、ProQuest学位论文数据库、ClinicalTrials.gov以及相关网站。
采用PICOS+E标准。纳入的研究报告了在美国出院回家的成年患者中,药学支持的TOC干预措施与常规护理的比较情况。研究需评估出院后结局(如再入院率、医院利用率)。纳入随机对照试验、队列研究或前后对照研究。两名评审员独立提取数据并评估研究质量。
系统评价共纳入56篇文章(n = 61858),其中32篇报告了全因30天再入院情况,并纳入荟萃分析。制定了一个分类法,将目标患者、干预类型和作为唯一干预者的药学人员进行分类。荟萃分析表明,与常规护理相比,药学支持的TOC干预措施使再入院几率降低了约32%(优势比[OR] = 0.68;95%可信区间[CI] = 0.61至0.75)。发现存在异质性(I² = 55%;P < 0.001)。分层荟萃分析表明,与无随访的研究相比,以患者为中心的随访干预措施降低了30天再入院率(OR = 0.70;CI = 0.63至0.78)。
药学支持的TOC项目与30天再入院几率的显著降低相关。